Literature DB >> 10213916

Urocortin and inflammation: confounding effects of hypotension on measures of inflammation.

D J Torpy1, E L Webster, E K Zachman, G Aguilera, G P Chrousos.   

Abstract

Urocortin, a newly isolated 40-amino-acid mammalian peptide homologous to corticotropin-releasing hormone (CRH), activates both CRH type 1 and 2 receptors, but may be an endogenous ligand for CRH receptor type 2. Urocortin given systemically inhibited heat-induced paw edema in the rat, and was therefore ascribed anti-inflammatory properties. We examined the effects of urocortin in the carrageenin-induced subcutaneous inflammation model. Rats were treated with urocortin 200 (n = 6) or 20 nmol/kg (n = 6); inflammatory exudates were reduced by approximately 30% compared to controls (n = 7) at both doses. However, since subcutaneous urocortin has been shown to reduce arterial blood pressure, we tested the hypothesis that its antiedema and antiextravasatory effects were secondary to arterial hypotension. Therefore, we examined the parallel effects of urocortin- and hydralazine-induced hypotension on acute inflammation induced by carrageenin in the rat. Rats were treated with subcutaneous carrageenin and control injections (n = 8), carrageenin and urocortin (20 nmol/kg, n = 9), or carrageenin and intraperitoneal hydralazine (10 mg/kg, n = 8). Mean arterial blood pressure was measured hourly for 7 h in 12 animals, and after 2 h, the nadir of treatment, in a further 13 animals. Rats were then sacrificed, and the inflammatory exudate volume and leukocyte count were measured. Mean exudate volumes were reduced from 4.8 +/- 0.5 ml (controls) to 2.4 +/- 0.3 ml (p = 0.004) and 2.9 +/- 0.6 ml (p = 0.007) in urocortin- and hydralazine-treated animals, respectively. Urocortin and hydralazine both produced a significant fall in blood pressure compared to controls, with mean arterial pressure 2 h after carrageenin injection falling to 51.0 +/- 4.1 (p < 0.001) and 34.6 +/- 4.6 (p < 0.001) vs. 92.9 +/- 3.7 mm Hg in controls, respectively. A significant positive correlation was noted between blood pressure and inflammatory exudate volume (r = 0. 52, p = 0.007). As both hydralazine and urocortin lowered blood pressure and inflammatory exudate volume, we suggest that the anti-inflammatory effects of urocortin and related neuropeptides may be nonspecific, acting through hypotension rather than through direct anti-inflammatory mechanisms. The use of inflammatory models which rely on extravasation may be inappropriate for the study of substances that produce hypotension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213916     DOI: 10.1159/000026380

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  10 in total

Review 1.  Placental stress factors and maternal-fetal adaptive response: the corticotropin-releasing factor family.

Authors:  Pasquale Florio; Filiberto M Severi; Pasquapina Ciarmela; Giovina Fiore; Giulia Calonaci; Angelica Merola; Claudio De Felice; Marco Palumbo; Felice Petraglia
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

Review 2.  Corticotropin releasing hormone and the skin.

Authors:  Andrzej Slominski; Blazej Zbytek; Michal Zmijewski; Radomir M Slominski; Sobia Kauser; Jacobo Wortsman; Desmond J Tobin
Journal:  Front Biosci       Date:  2006-09-01

3.  Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response.

Authors:  Elena Gonzalez-Rey; Alejo Chorny; Nieves Varela; Gema Robledo; Mario Delgado
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2.

Authors:  Nicolas Cenac; Anne-Marie Coelho; Cathy Nguyen; Steven Compton; Patricia Andrade-Gordon; Wallace K MacNaughton; John L Wallace; Morley D Hollenberg; Nigel W Bunnett; Rafael Garcia-Villar; Lionel Bueno; Nathalie Vergnolle
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

5.  Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease.

Authors:  E Gonzalez-Rey; A Fernandez-Martin; A Chorny; M Delgado
Journal:  Gut       Date:  2006-01-09       Impact factor: 23.059

6.  Fractal dynamics of heart beat interval fluctuations in corticotropin-releasing factor receptor subtype 2 deficient mice.

Authors:  Oliver Stiedl; Michael Meyer
Journal:  Integr Physiol Behav Sci       Date:  2002 Oct-Dec

7.  Fractal dynamics in circadian cardiac time series of corticotropin-releasing factor receptor subtype-2 deficient mice.

Authors:  O Stiedl; M Meyer
Journal:  J Math Biol       Date:  2003-03-19       Impact factor: 2.259

8.  Fractal rigidity by enhanced sympatho-vagal antagonism in heartbeat interval dynamics elicited by central application of corticotropin-releasing factor in mice.

Authors:  M Meyer; O Stiedl
Journal:  J Math Biol       Date:  2006-03-06       Impact factor: 2.259

9.  Systemic administration of urocortin after intracerebral hemorrhage reduces neurological deficits and neuroinflammation in rats.

Authors:  Hock-Kean Liew; Cheng-Yoong Pang; Chih-Wei Hsu; Mei-Jen Wang; Ting-Yi Li; Hsiao-Fen Peng; Jon-Son Kuo; Jia-Yi Wang
Journal:  J Neuroinflammation       Date:  2012-01-19       Impact factor: 8.322

Review 10.  Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.

Authors:  Per Anderson; Mario Delgado
Journal:  J Cell Mol Med       Date:  2008-06-28       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.